Skip to main content
Loading

Kineta

Monday, February 26, 2024
Uris
Oncology
Kineta (Nasdaq: KA) is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives. Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the major challenges with current cancer therapy. The company’s immuno-oncology pipeline includes KVA12123, a novel VISTA blocking immunotherapy currently in a Phase 1/2 clinical trial in patients with advanced solid tumors, and a preclinical monoclonal antibody targeting CD27.
Speakers
Jacques Bouchy, EVP Investor Relations and Business Development - Kineta

State

WA

Country

United States

Website

https://kinetabio.com/

CEO/Top Company Official

Shawn Iadonato

Lead Product in Development

KVA12123, a novel VISTA blocking immunotherapy currently in a Phase 1/2 clinical trial in patients with advanced solid tumors

Development Phase of Primary Product

Phase I

Number Of Unlicensed Products

3
Testimonials

Double Helix


 

Supporting Bank Sponsor


 

Premier Sponsors

Conference Sponsors


 

Media Partner


 

Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.

SIGN UP